Literature DB >> 1744591

Human immunodeficiency virus infection of eosinophils in human bone marrow cultures.

A R Freedman1, F M Gibson, S C Fleming, C J Spry, G E Griffin.   

Abstract

Normal human bone marrow, cultured in vitro with interleukin 5 to promote eosinophil production and maturation, was inoculated with cell-free isolates of human immunodeficiency virus type 1 (HIV-1). CD4 expression by eosinophil precursors, determined by immunocytochemistry, was found to be greatest early in their maturation with a rapid decline after 28 d in culture. Productive HIV infection of eosinophil precursors was detected 14 d after inoculation, by a combination of immunostaining for HIV-1 p24 and gp41/160 and in situ hybridization for viral RNA, together with assay of culture supernatants for p24 antigen and reverse transcriptase activity. Thus, eosinophils are susceptible to productive HIV-1 infection in vitro and may be an important reservoir for the virus in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1744591      PMCID: PMC2119059          DOI: 10.1084/jem.174.6.1661

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  17 in total

Review 1.  The immunobiology of eosinophils.

Authors:  P F Weller
Journal:  N Engl J Med       Date:  1991-04-18       Impact factor: 91.245

2.  Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow.

Authors:  T M Folks; S W Kessler; J M Orenstein; J S Justement; E S Jaffe; A S Fauci
Journal:  Science       Date:  1988-11-11       Impact factor: 47.728

Review 3.  Hematologic manifestations of parasitic infections.

Authors:  M E Conrad
Journal:  Semin Hematol       Date:  1971-07       Impact factor: 3.851

4.  Single amino-acid changes in HIV envelope affect viral tropism and receptor binding.

Authors:  A Cordonnier; L Montagnier; M Emerman
Journal:  Nature       Date:  1989-08-17       Impact factor: 49.962

5.  IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity.

Authors:  M E Rothenberg; J Petersen; R L Stevens; D S Silberstein; D T McKenzie; K F Austen; W F Owen
Journal:  J Immunol       Date:  1989-10-01       Impact factor: 5.422

6.  Macrophage-active colony-stimulating factors enhance human immunodeficiency virus type 1 infection in bone marrow stem cells.

Authors:  K Kitano; C N Abboud; D H Ryan; S G Quan; G C Baldwin; D W Golde
Journal:  Blood       Date:  1991-04-15       Impact factor: 22.113

7.  Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions.

Authors:  A D Hoffman; B Banapour; J A Levy
Journal:  Virology       Date:  1985-12       Impact factor: 3.616

8.  Human immunodeficiency virus infection of megakaryocytic cells.

Authors:  M Sakaguchi; T Sato; J E Groopman
Journal:  Blood       Date:  1991-02-01       Impact factor: 22.113

9.  Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF.

Authors:  E J Clutterbuck; E M Hirst; C J Sanderson
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

10.  Human eosinophils express CD4 protein and bind human immunodeficiency virus 1 gp120.

Authors:  D R Lucey; D I Dorsky; A Nicholson-Weller; P F Weller
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  12 in total

Review 1.  Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1).

Authors:  B J Doranz; J F Berson; J Rucker; R W Doms
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

2.  Transcription factor GATA-1 potently represses the expression of the HIV-1 coreceptor CCR5 in human T cells and dendritic cells.

Authors:  Mark S Sundrud; Scott E Vancompernolle; Karla A Eger; Tullia C Bruno; Arun Subramaniam; Srinivas Mummidi; Sunil K Ahuja; Derya Unutmaz
Journal:  Blood       Date:  2005-08-09       Impact factor: 22.113

Review 3.  Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.

Authors:  D R Lucey; M Clerici; G M Shearer
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

4.  Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates resulting from the delta ccr5 mutation.

Authors:  S Rana; G Besson; D G Cook; J Rucker; R J Smyth; Y Yi; J D Turner; H H Guo; J G Du; S C Peiper; E Lavi; M Samson; F Libert; C Liesnard; G Vassart; R W Doms; M Parmentier; R G Collman
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Eosinophilia in patients infected with the human immunodeficiency virus.

Authors:  A Tietz; L Sponagel; P Erb; H Bucher; M Battegay; W Zimmerli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-09       Impact factor: 3.267

Review 6.  Biology of the eosinophil.

Authors:  Carine Blanchard; Marc E Rothenberg
Journal:  Adv Immunol       Date:  2009       Impact factor: 3.543

7.  Eosinophil survival and apoptosis in health and disease.

Authors:  Yong Mean Park; Bruce S Bochner
Journal:  Allergy Asthma Immunol Res       Date:  2010-03-24       Impact factor: 5.764

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  Effect of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine on establishment of human immunodeficiency virus type 1 infection in cultured CD8+ lymphocytes.

Authors:  L Mercure; B J Brenner; D Phaneuf; C Tsoukas; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

10.  The influence of different helminth infection phenotypes on immune responses against HIV in co-infected adults in South Africa.

Authors:  Zilungile L Mkhize-Kwitshana; Myra Taylor; Pieter Jooste; Musawenkosi Lh Mabaso; Gerhard Walzl
Journal:  BMC Infect Dis       Date:  2011-10-14       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.